2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting
SHANGHAI,Dec. 9,2024-- December 8,2024,Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versu